HBOX Therapies GmbH is developing a platform technology for hyperbaric blood oxygenation, specifically through a miniaturized respiratory assist device that offers a non-invasive alternative to traditional ventilation methods. This technology aims to improve survival rates and reduce complications and hospital stays for patients experiencing lung failure.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients experiencing lung failure often require invasive ventilation, which necessitates induced comas and can lead to complications, extended hospital stays, and reduced survival rates. Current respiratory support methods lack non-invasive alternatives that can effectively improve blood oxygenation.
Solution
HBOX Therapies GmbH is developing a miniaturized respiratory assist device that offers a non-invasive alternative to traditional invasive ventilation for patients with lung failure. This platform technology for hyperbaric blood oxygenation aims to improve patient outcomes by reducing the need for induced comas, thereby potentially lowering complication rates and shortening hospital stays. The core value proposition lies in enhancing survival probabilities through a less intrusive respiratory support system.
Target Audience
The primary target audience includes hospitals, medical professionals, and patients experiencing lung failure who require respiratory support.
Features
- Miniaturized respiratory assist device for non-invasive hyperbaric blood oxygenation.
- Aims to reduce the need for invasive ventilation and induced comas.
- Designed to lower complication rates associated with traditional ventilation methods.
- Intended to shorten hospital stays for lung failure patients.